MR-compliant content
Every piece of content reviewed against the relevant regulatory framework. India's CDSCO, EU's MDR, US FDA — the rules differ; the discipline doesn't.
Healthcare · MedTech
Healthcare and MedTech marketing has a credibility ceiling no other category has. The audience is sceptical. The regulator is watching. The buyer journey is long. The marketing model that works in D2C wellness will get you sued in regulated diagnostics — and the model that works in pharma is overkill for hospital equipment.
The problem
Marketers used to D2C playbooks see the healthcare audience and overreach — claims that won't survive scrutiny, content that triggers compliance, paid ads that get rejected. The result is brand damage that takes years to repair.
How I help
Every piece of content reviewed against the relevant regulatory framework. India's CDSCO, EU's MDR, US FDA — the rules differ; the discipline doesn't.
Hospital procurement is one channel. Specialist physicians are another. Distributors are a third. Patients (where allowed) are a fourth.
In healthcare, third-party credibility outranks brand voice. KOL programmes — done with integrity — are often the highest-leverage marketing investment.
India MedTech exporting needs content calibrated for EU/US standards. Different claim language, different evidence depth.
How it works
Regulatory framework, claim limitations, content review process — defined first.
Hospital, specialist, distributor, patient (where allowed). Each its own track.
Clinically grounded content. KOL identification and programme design.
Weekly review. Lead tracking by channel. Distributor pipeline visibility.
Selected work
Anonymised at client request — substance unchanged.
Distributor pipeline
MedTech selling runs through hospitals and distributors. Sample, demo, evaluation, PO — each stage tracked, GST-compliant quoting built in.
Try Vyndeal freeCompliant content delivery
Clinical content writers, MR-aware reviewers, KOL piece producers. The compliance discipline the category demands.
See QuiamoFAQ
Pharma-adjacent and MedTech, mostly. True pharma marketing in India is highly regulated and usually run by specialised agencies.
D2C wellness brands are closer to D2C than to MedTech. The maths model applies; claim discipline is still important.
Yes. Hospital chains marketing to patients (especially private/multi-specialty) is a discrete category.
No — that's a legal/regulatory affairs function. I work with your team to keep marketing inside the lines they draw.
Yes — Indian MedTech going to EU/US needs different content depth and claim discipline.
Book a 30-minute discovery call. We'll work out fit, scope and shape — no deck, no preamble.
🌍 Global enquiries
From Helsinki to Hanoi, Geneva to São Paulo — engagements run async-first with on-site visits where they matter. Drop a line and I'll respond within one working day.
18+ years across global B2B and D2C. Six working languages. Async-by-default operating cadence calibrated for distributed teams. India hours overlap with Europe, the Middle East, Asia-Pacific and the Americas — meaning live-hours coverage of every major target market.
Past engagements span the EU, the UK, the USA, the UAE, Latin America, and Southeast Asia — through agency, in-house and consulting roles.